Abstract
Background Over recent years smartphone-based monitoring has been recognized as a useful instrument in psychiatric research. Due to the phasic character of affective symptoms, mobile assessments of passive sensor data as well as active self-reported data via the participants smartphone might represent a cost-efficient and highly useful tool for prospective prediction of mood changes. Despite these promising opportunities, smartphone-based monitoring in psychiatry is still limited to pilot studies often focusing on a single disorder while large-scale, transdiagnostic studies are widely absent.
Objectives The present paper describes the functionality and development of the Remote Monitoring Application in Psychiatry (ReMAP). We aimed to investigate the technical feasibility, and the acceptance of the ReMAP app for the continuous assessment of affective symptoms among different patient groups.
Methods The ReMAP app was distributed among a sample of n=997 composed of healthy control participants and psychiatric patients. Continuous passive sensor data were assessed comprising acceleration, geolocation, as well as walking distance and steps. Further, participants optionally provided standardized self-reports on mood and sleep, as well as voice samples. Technical feasibility and acceptance were assessed based on the amount and frequency of transferred data events, as well as participation duration. Preliminary results are presented while data collection is ongoing.
Results Retention rates of 90.25% for the required minimum study duration of two weeks and 33.09% for one year respectively were achieved. On average, users participated for 150 days. An average of 51.83 passive events per day per participant was collected, with an average rate of 73.50% of days during participation containing passive events. An average of 34.59 active self-report events were transferred per participant, with a considerable range across participants (0-552 events). While clinical and non-clinical participant subgroups did not differ in participation duration, or in quantity or rate of passive or active data transfer, the rate of days with transferred passive data was considerably higher and less heterogeneous in iOS (mean=91.85%, SD=21.25) as compared to Android users (mean=63.04%, SD=35.09).
Conclusions The ReMAP app is technically feasible and generally well accepted and therefore represents a viable complementary tool for the continuous assessment of affective symptoms in large-scale transdiagnostic psychiatric studies. Future studies should account for the observed systematic differences between operating systems.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding was provided by the DFG Projectnumber 44541416-TRR 58 (CRC-TRR58, Projects C09 and Z02 to Udo Dannlowski) and the Interdisciplinary Center for Clinical Research (IZKF) of the medical faculty of Muenster (Grant Dan3/012/17 to Udo Dannlowski and SEED 11/19 to NO), as well as the Innovative Medizinische Forschung (IMF) of the medical faculty of Muenster (Grants OP121710 to NO and TH; LE121703 and LE121904 to EJL). Further DFG funding in the context of the Forschungsgruppe/Research Unit FOR2107 was received by: Tilo Kircher (speaker FOR2107; DFG grant numbers KI 588/14-1, KI 588/14-2, KI 588/15-1, KI 588/17-1), Udo Dannlowski (co-speaker FOR2107; DA 1151/5-1, DA 1151/5-2, DA 1151/6-1), Axel Krug (KR 3822/5-1, KR 3822/7-2), Igor Nenadic (NE 2254/1-2), Carsten Konrad (KO 4291/3-1), Marcella Rietschel (RI 908/11-1, RI 908/11-2), Markus Noethen (NO 246/10-1, NO 246/10-2), Stephanie Witt (WI 3439/3-1, WI 3439/3-2), Andreas Jansen (JA 1890/7-1, JA 1890/7-2), Tim Hahn (HA 7070/2-2, HA7070/3, HA7070/4), Bertram Mueller-Myhsok (MU1315/8-2), Astrid Dempfle (DE 1614/3-1, DE 1614/3-2), Petra Pfefferle (PF 784/1-1, PF 784/1-2), Harald Renz (RE 737/20-1, 737/20-2), Carsten Konrad (KO 4291/4-1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants received financial compensation. The study was approved by the local institutional review board (IRB = the ethics committee of the Medical Faculty of the University of Muenster, Germany) and written informed consent was obtained from all participants before study participation.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data will be made available upon request
